Moreover, hCNT1 expression shows a trend to diminish in some cancer types such as gynecologic tumors, breast cancer and pancreatic cancer [21, 22, 32], which clearly could impair chemosensitivity to gemcitabine. This evidence concerns the gene SLC28A1 and breast carcinoma.